

03/20/00



J0662 U.S. PTO

U.S. PTO

438

03/20/00

UTILITY PATENT APPLICATION TRANSMITTAL <small>(Only for new nonprovisional applications under 37 CFR 1.53(b))</small>		Attorney Docket No. 0660-0172-0 CONT
		First Inventor or Application Identifier Maryse GIBERT
		Title CLOSTRIDIUM TOXIN, AND PROCESS FOR THE PREPARATION OF IMMUNOGENIC COMPOSTIONS

APPLICATION ELEMENTS <small>See MPEP chapter 600 concerning utility patent application contents</small>		ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Washington, DC 20231
<p>1. <input checked="" type="checkbox"/> Fee Transmittal Form (e.g. PTO/SB/17) (Submit an original and a duplicate for fee processing)</p> <p>2. <input checked="" type="checkbox"/> Specification Total Pages 28</p> <p>3. <input checked="" type="checkbox"/> Drawing(s) (35 U.S.C. 113) Total Sheets 9</p> <p>4. <input type="checkbox"/> Oath or Declaration Total Pages a. <input type="checkbox"/> Newly executed (original or copy) b. <input type="checkbox"/> Copy from a prior application (37 C.F.R. §1.63(d)) <i>(for continuation/divisional with box 15 completed)</i> i. <input type="checkbox"/></p> <p>DELETION OF INVENTOR(S) <small>Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §1.63(d)(2) and 1.33(b)</small></p> <p>5. <input type="checkbox"/> Incorporation By Reference The entire disclosure of the prior application, is considered to be part of the disclosure of the accompanying application and is hereby incorporated by reference therein</p>		ACCOMPANYING APPLICATION PARTS 6. <input type="checkbox"/> Assignment Papers (cover sheet & document(s)) 7. <input type="checkbox"/> 37 C.F.R. §3.73(b) Statement <small>(when there is an assignee)</small> <input type="checkbox"/> Power of Attorney 8. <input type="checkbox"/> English Translation Document <i>(if applicable)</i> 9. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations 10. <input checked="" type="checkbox"/> Preliminary Amendment 11. <input checked="" type="checkbox"/> White Advance Serial No. Postcard 12. <input type="checkbox"/> Small Entity Statement(s) <input type="checkbox"/> Statement filed in prior application. Status still proper and desired. 13. <input type="checkbox"/> Certified Copy of Priority Document(s) <i>(if foreign priority is claimed)</i> 14. <input checked="" type="checkbox"/> Other: REQUEST FOR PRIORITY; LIST OF INVENTORS NAMES AND ADDRESSES; VERIFICATION OF TRANSLATION; SEQUENCE LISTING
<p>15. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below:</p> <p><input checked="" type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application no.: PCT/FR98/01999</p> <p>Prior application information: Examiner: Group Art Unit:</p> <p>16. Amend the specification by inserting before the first line the sentence:</p> <p><input checked="" type="checkbox"/> This application is a <input checked="" type="checkbox"/> Continuation <input type="checkbox"/> Division <input type="checkbox"/> Continuation-in-part (CIP) of International Application No. PCT/FR98/01999 Filed on September 17, 1998</p> <p><input type="checkbox"/> This application claims priority of provisional application Serial No. Filed</p>		
<p>17. CORRESPONDENCE ADDRESS</p> <p>OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C. FOURTH FLOOR 1755 JEFFERSON DAVIS HIGHWAY ARLINGTON, VIRGINIA 22202 (703) 413-3000 FACSIMILE: (703) 413-2220</p>		

Name: Norman F. Oblon	Registration No.: 24,618
Signature:	Date: 3/20/00
Name: Daniel J. Pereira, Ph.D.	Registration No.: P45,518

Docket No. 0660-0172-0 CONT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: MARYSE GIBERT ET AL

FILING DATE: Herewith

FOR: CLOSTRIDIUM TOXIN, AND PROCESS FOR THE PREPARATION OF IMMUNOGENIC COMPOSITIONS

LIST OF INVENTORS' NAMES AND ADDRESSES

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Listed below are the names and addresses of the inventors for the above-identified patent application.

Maryse GIBERT

1 avenue Julia
92160 Antony, France

Michel-Robert POPOFF

18 ter, rue Galliera
92140 Clamart, France

A declaration containing all the necessary information will be submitted at a later date.

Respectfully Submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon
Registration No. 24,618

Daniel J. Pereira, Ph.D.
Registration No. P45,518

Fourth Floor
1755 Jefferson Davis Highway
Arlington, Virginia 22202
Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 11/98)

0660-0172-0CONT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF:

MARYSE GIBERT ET AL

:ATTN: APPLICATION DIVISION

SERIAL NO: NEW APPLICATION

:

FILED: HEREWITH

:

FOR: CLOSTRIDIUM TOXIN, AND
PROCESS FOR THE PREPARATION
OF IMMUNOGENIC COMPOSITIONS

PRELIMINARY AMENDMENT

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Prior to examination on the merits, please amend the above-identified application as follows.

IN THE CLAIMS

Please cancel Claims 18, 20 and 23.

Please amend the claims as follows:

Claim 1, line 1, change "characterized in that" to --wherein--.

Claim 2, line 1, change "characterized in that" to --wherein--.

3. (Amended) A nucleic acid according to claim 1 [or claim 2, characterized in that it is] wherein the nucleic acid is a promoter of the gene for the beta 2 toxin of *Clostridium perfringens* or a fragment thereof.

Claim 4, line 1, change "characterized in that" to --wherein--.

Claim 5, line 1, change "characterized in that" to --wherein--.

6. (Amended) [An] The expression cassette according to claim 4 [or claim 5, characterized in that it] further comprising [comprises] a secretion signal between the nucleic acid and the transgene.

7. (Amended) An expression cassette according to [any one of claims 4 to 6, characterized in that] Claim 4, wherein the transgene codes for a toxin or a fragment or a variant of the toxin.

Claim 8, line 1, change "characterized in that" to --wherein--.

9. (Amended) A vector comprising a nucleic acid according to claim 1 [or an expression cassette according to claim 4].

Claim 10, line 1, change "characterized in that" to --wherein--.

Claim 11, line 1, change "characterized in that" to --wherein--.

12. (Amended) A recombinant cell comprising a nucleic acid according to Claim 1 [or an expression cassette according to claim 4 or a vector according to claim 9].

13. (Amended) A cell according to claim 12, [characterized in that] wherein it is a prokaryote cell [, preferably a bacterium].

15. (Amended) A process for producing a polypeptide, [characterized in that it comprises] comprising culturing a recombinant cell according to claim 12 [comprising an

expression cassette according to claim 4 or a vector according to claim 9, the transgene coding] wherein the nucleic acid codes for said polypeptide.

16. (Amended) A process according to claim 14 [or claim 15, characterized in that] wherein the cell is a bacterium from the genus *Clostridium*.

17. (Amended) A process according to [any one of claims 14 to 16 for producing] Claim 14, wherein said process produces a toxin or a toxoid.

Please add the following claims:

--24. A process for producing a polypeptide comprising expressing the nucleic acid of Claim 1.

25. An isolated recombinant beta 2 toxin.
26. A vector comprising the cassette according to claim 4.
27. A recombinant cell comprising the expression cassette of claim 4.
28. A recombinant cell comprising the vector of claim 9
29. A recombinant cell comprising the vector of Claim 26.
30. The cell according to claim 12, wherein the cell is a bacterium.
31. The cell according to claim 27, wherein the cell is a bacterium.
32. The cell according to claim 28, wherein the cell is a bacterium.
33. The cell according to claim 29, wherein the cell is a bacterium.
34. A process according to claim 15, wherein the cell is a bacterium from the genus *Clostridium*.

35. A process for producing a polypeptide, comprising culturing the recombinant cell of claim 27.

36. A process for producing a polypeptide, comprising culturing the recombinant cell of claim 28.

37. A process for producing a polypeptide, comprising culturing the recombinant cell of claim 29.

38. A process for preparing an immunogenic composition comprising expressing one or more toxins or the corresponding toxoids in a cell according to claim 12;

harvesting a supernatant ;

optionally, treating the supernatant to purify or concentrate the toxin or toxoid;

inactivating the toxin or toxoid; and

optionally packaging the inactivated toxin or toxoid.

39. A process for preparing an immunogenic composition comprising expressing one or more toxins or the corresponding toxoids in a cell according to claim 27;

harvesting a supernatant ;

optionally, treating the supernatant to purify or concentrate the toxin or toxoid;

inactivating the toxin or toxoid; and

optionally packaging the inactivated toxin or toxoid.

40. A process for preparing an immunogenic composition comprising expressing one or more toxins or the corresponding toxoids in a cell according to claim 28;

harvesting a supernatant ;

optionally, treating the supernatant to purify or concentrate the toxin or toxoid; inactivating the toxin or toxoid; and optionally packaging the inactivated toxin or toxoid.

41. A process for preparing an immunogenic composition comprising expressing one or more toxins or the corresponding toxoids in a cell according to claim 29;

harvesting a supernatant ; optionally, treating the supernatant to purify or concentrate the toxin or toxoid; inactivating the toxin or toxoid; and optionally packaging the inactivated toxin or toxoid.--

REMARKS

Claims 1-17, 19, 21, 22, and 24-41 are active in the present application. The claims are amended for clarity and to remove multiply dependent claims. No new matter has been added by the amendments submitted above.

Applicants submit that the present application is now in condition for examination on the merits. Early notice of such is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon
Attorney of Record
Registration No. 24,618

Daniel J. Pereira, Ph.D.
Registration No. P45,518

Crystal Square Five - Fourth Floor
1755 Jefferson Davis Highway
Arlington, VA 22202
(703) 413-3000
Fax #: (703)413-2220
NFO/DJPER/js

I:\User\DJPER\06600172.pr

VERIFICATION OF A TRANSLATION
(VERIFICATION D'UNE TRADUCTION)

I, the below named translator, hereby declare that :

My name and post office address are as stated below :

That I am knowledgeable in the English language and in the language in which the below identified international application was filed, and that I believe the English translation of the international application n° PCT/FR 98/01999 is a true and complete translation of the above identified international application as filed.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true ; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such wilful false statements may jeopardize the validity of the application or any patent issued thereon.

Date March 14, 2000

Full name of the translator DESAIX Anne
(Nom et prénom du traducteur)

Signature of the translator 
(Signature du traducteur)

Post Office Address (Adresse postale)
.....

ERNEST GUTMANN-YVES PLASSERAUD S.A.
3 rue Chauveau-Lagarde
FR-75008 PARIS

CLOSTRIDIUM TOXIN, AND PROCESS FOR THE PREPARATION OF IMMUNOGENIC COMPOSITIONS.

The present invention relates to novel nucleic acids with a transcriptional promoter activity. It also relates to a process for preparing recombinant polypeptides using these nucleic acids, and to recombinant cells containing these nucleic acids. The invention also relates to a novel process for preparing antigens or 5 fragments of antigens, in particular bacterial toxins, more preferably *Clostridium* toxins, for preparing immunogenic and/or vaccine compositions. Still further, it relates to immunogenic and/or vaccine compositions with improved properties.

More particularly, the present invention relates to the field of production of bacterial toxic proteins, in particular toxins from *Clostridium* or other pathogenic 10 organisms. In particular, it relates to the improved production of these toxins, with the aim of producing immunogenic preparations with an increased vaccinating power.

Diseases of bacterial origin (cholera, dysentery, enteritis, etc) are a major cause of death in man and in animals. Such diseases are essentially alimentary in 15 origin, linked to the presence of pathogenic bacteria in ingested elements which colonise the mucosal walls then cause toxicity and tissue necrosis. Pathogenic bacteria come from different genera, particular examples being *Actinomycetes*, *Bacillus*, *Bordetella*, *clamydia*, *Clostridium*, *Corynebacterium*, *Escherichia*, *Fusobacterium*, *Listeria*, *Mycobacterium*, *Mycoplasma*, *Salmonella*, 20 *Staphylococcus*, *Treponemo* and *Vibro*. Of these pathogenic bacteria, *Clostridium* bacteria form a large class, among which the following species deserve mention: *C. absonum*, *C. baratii*, *C. bifermentans*, *C. chauvei*, *C. difficile*, *C. ghonii*, *C. lituseburens*, *C. novyi*, *C. perfringens*, *C. septicum*, *C. sordellii*, *C. subterminale* and *C. tetani*.

25 The pathogenicity of these pathogenic bacteria has been shown to be linked to their production of toxins or enterotoxins. The large majority of such toxins have now been identified and characterized.

Thus the pathogenicity of strains of *Clostridium septicum*, known to be 30 responsible for atraumatic gangrene, is linked to the expression of a single lethal factor, alpha toxin, the gene of which has been cloned (Ballard et al., Infection and Immunity 63 (1995), 340). The toxin produced by strains of *Clostridium sordellii*

has been designated cytotoxin Cs Cyt. Strains of *C. perfringens* are generally classified into 5 types (A-E) depending on the nature of the toxins they produce (alpha, beta, epsilon, iota and enterotoxin). The toxicity of *C. tetani* is linked to the production of a toxin, and *Bordetella* produces pertussis toxin while *C. tetani* produces tetanus toxin. Other toxins will be indicated in the text below.

Currently available treatments are essentially prophylactic in nature. Thus vaccine preparations are produced from cultures of pathogenic bacteria strains. The supernatants containing the toxins are then harvested and undergo different concentration and/or partial purification steps. The supernatants or their filtrates/concentrates then undergo an inactivation step, to produce non virulent toxins, but which retain their immunogenic power (toxoids). Different techniques are available for inactivating toxins, in particular chemical or genetic techniques which will be described below in detail. Further, prior to the inactivation step, supernatants from cultures of different pathogenic organisms are usually combined to obtain cocktails of toxins with the aim of preparing polyvalent vaccines.

Examples of commercially available vaccines are Miloxan®, sold by Rhône-Mérieux (Mérial), France, which protects animals against toxi-infections and enterotoxemia due to strains of *Clostridium perfringens* and *Clostridium sordelli*. More particularly, that vaccine preparation contains toxoids of types B, C and D of *Clostridium perfringens*, of *Clostridium septicum*, of *Clostridium novyi*, of *Clostridium tetani*, of *Clostridium chauvei* and of *Clostridium sordellii*. A further example of a polyvalent vaccine is Gletvax5®, sold by Mallinckrodt Veterinary, France, providing protection against colibacilosis in young swine and enteritis from type C *Clostridium perfringens*. More particularly, that vaccine contains *E. coli* antigens, as well as toxoids of the beta toxin of type C *Clostridium perfringens*.

Currently available vaccines, however, have a certain number of disadvantages. They are essentially mixtures of culture supernatants, the composition of which is not precisely defined and for which the reproducibility is thus not entirely assured. Further, the production of polyvalent vaccines protecting against different pathogenic organisms involves separate fermentation of different organisms, meaning that on an industrial scale, culture conditions and safety

standards are highly restrictive. Further, the efficiency of some vaccines against certain toxins is limited, in particular those produced in small quantities by pathogenic organisms.

There is thus a genuine need for improving the conditions for preparing, the 5 quality and the efficiency of vaccines against bacterial toxins. The present invention provides an advantageous solution to these problems.

The present invention provides novel nucleic acids enabling expression of transgenes in bacteria, in particular *Clostridium* type bacteria. The invention also provides constructions enabling larger quantities of toxins, in particular for vaccine 10 purposes, to be produced in bacteria, in particular in *Clostridium* type bacteria. In particular, the present invention provides strains of recombinant bacteria, in particular *Clostridium* type bacteria, enabling the amplified production of toxins, either *Clostridium* toxins or toxins from other pathogenic organisms. The invention also provides strains of recombinant bacteria, in particular *Clostridium* type bacteria, 15 enabling a number of toxins to be simultaneously produced.

The invention thus describes a process for producing recombinant toxins enabling the immunogenic character, and thus their protective effect, of vaccine preparations to be increased.

The invention also describes the production of novel toxins by a 20 recombinant route, enabling the range of existing vaccines to be increased, in particular as regards the beta 2 toxin of *Clostridium perfringens* or other toxins which are produced in small quantities by pathogenic organisms, or which are of low immunogenicity.

The invention also provides a considerably easier industrial implementation 25 in that the volumes of supernatants produced and the diversity of the productive organisms used can be significantly reduced.

More particularly, in a first aspect, the invention relates to nucleic acids and 30 genetic constructions for improving the production of proteins in bacteria, in particular bacterial toxins in bacteria of the genus *Clostridium*, in particular *Clostridium perfringens*.

Thus the Applicant has isolated, from the genome of a type C *Clostridium perfringens* strain, the complete gene coding for a toxin, designated beta 2 toxin (SEQ ID n° 1). A study of the gene obtained has showed that that gene also comprises, at the 5' end, a transcriptional promoter region (SEQ ID n° 2), which is 5 effective in bacteria in particular in bacteria from the genus *Clostridium*, in particular *Clostridium perfringens*.

More particularly, in its first aspect, the invention provides a nucleic acid characterized in that it has a transcriptional promoter activity and in that it comprises:

- 10 (a) all or a portion of sequence SEQ ID n° 2 or a variant thereof; or
- (b) a sequence hybridising with all or part of the complementary strand of sequence SEQ ID n° 2.

More preferably, the nucleic acid of the invention comprises all or a portion of sequence SEQ ID n° 2.

15 Advantageously, the nucleic acid of the invention is constituted by a promoter of the gene for the beta 2 toxin of *Clostridium perfringens* or a fragment thereof.

The term "nucleic acid" as used in the invention means any deoxyribose 20 nucleic acid (DNA) or ribonucleic acid (RNA). More particularly, the DNA can be a complementary DNA (cDNA), a genomic DNA (gDNA) or a synthetic DNA. In the present invention, the term "nucleic acid" is also synonymous with "polynucleotide". The nucleic acids of the invention can be of a variety of origins, in particular bacterial, synthetic or semi-synthetic. They may be isolated using any known molecular biological technique, using structural data and sequences provided 25 in the present application. Thus these nucleic acids can be isolated from libraries using hybridisation techniques. They can also be synthesised chemically or genetically.

The term "portion" or "fragment" of nucleic acid means any nucleic acid comprising at least a portion of the sequence under consideration (for example 30 sequence SEQ ID n° 2) and which retains a transcriptional promoter activity. The sequence portion advantageously contains at least 50 bp, more preferably at least

100 bp. These “portions” can readily be generated using conventional molecular biological techniques, either by enzymatic cleavage and digestion from the fragments described, or by synthesis using nucleic acid synthesisers.

The term “hybridising” as used in the present invention means any hybridisation under normal conditions, which may be stringent or non stringent, as defined below. An example of stringent hybridisation conditions is: Hybridisation at 42°C, 50% formamide, 5 X SSC, 1 X Denhardt; Wash at 65°C in 0.1 X SSC, 0.1% SDS. Non stringent conditions are: Hybridisation at 37°C, 40% formamide, 5 X SSC, 1 X Denhardt; Wash at 50°C in 1 x SSC, 0.1% SDS. Stringent conditions are particularly suitable when the nucleic acids are present in small quantities and/or are in purified form. Non stringent conditions are more suitable when the nucleic acid is present in larger quantities and are significantly represented in the sample. Advantageously, “hybridising” sequences are sequences which hybridise under stringent conditions, and which thus have a high degree of structural homology with the sequence under consideration (for example SEQ ID n° 2) or its fragments. Further, hybridising sequences can include a region enabling hybridisation and a contiguous region which is not hybridising, but corresponding to flanking regions.

In addition, the transcriptional promoter activity of the “fragments” or “portions” and “hybridising sequences” can readily be determined by the skilled person using the methodology described in the examples. In particular, the activity of the fragments/hybridising sequences can be verified by introducing these nucleic acids to the 5' end of a marker gene, then studying the expression of that marker in a population of cells such as bacteria from the genus *Clostridium*, in particular *Clostridium perfringens*.

The examples below show that the nucleic acids of the invention can significantly amplify the expression of a protein in a bacterium, in particular in a *Clostridium perfringens*.

Thus for a wild strain producing beta 2 toxin, the production level is increased by a factor of about 40 to 80 in the presence of a nucleic acid of the invention. Further, the following examples show that these nucleic acids enable the expression of significant levels of heterologous proteins in bacteria from the genus

Clostridium. In particular, the examples show that the nucleic acids of the invention can produce heterologous toxins in these bacteria.

In this respect, the invention also concerns a cassette for expression of a transgene, characterized in that it comprises, in the 5' → 3' direction:

- 5 • a nucleic acid as defined above; and
• said transgene.

In the cassette of the invention, the nucleic acid and the transgene are operationally connected together (i.e., so that the nucleic acid enables expression of said transgene).

10 Advantageously, the cassette of the invention further comprises a transcriptional terminator, at the 3' end of the transgene.

Further, the cassette of the invention can also advantageously comprise a secretion signal which can induce or increase secretion of the expression product of the transgene by the cells. Advantageously, this secretion signal is located between 15 the nucleic acid of the invention and the transgene, in the same reading frame as the latter.

To this end, the inventors have also demonstrated the existence in the identified gene of such a secretion signal, which is particularly active in bacteria from the genus *Clostridium*. This signal is represented by residues 268-357 in 20 sequence SEQ ID n° 1, and separately in SEQ ID n° 3. This signal, or any variant or active fragment thereof, constitutes an advantageous embodiment of the invention.

As indicated above, the invention is particularly suitable for the production of toxins or fragments or variants of toxins. Thus in a particular embodiment, the expression cassette of the invention is characterized in that the transgene codes for a 25 toxin or a toxin fragment or variant. More particularly still, the transgene codes for a toxin or a toxin fragment or variant of a pathogenic bacterium.

The term "toxin" as used in the invention means any peptide, polypeptide or protein produced by a pathogenic bacteria, and involved in said pathogenic activity. It may be a factor which is directly responsible for the toxicity of the bacterium, or it 30 may participate in that toxicity. A toxin "fragment" can be constituted by any portion of a toxin, which has retained certain immunogenic features of the toxin. In

particular, bacterial toxins have been described as often presenting different distinct functional domains, in particular a domain involved in toxic activity (catalytic site) distinct from other domains involved in site recognition or in interactions with partners. A toxin "fragment" of the invention is advantageously constituted by a 5 domain which is deprived of toxic activity, but which retains an immunogenic power. A toxin variant may, for example, be constituted by a derivative resulting from genetic modifications of the sequence coding for said toxin or toxin fragment. Examples of such genetic modifications are mutations, deletions, fusions, etc.. In general, mutations affect 1 to 10 residues, preferably 1 to 5 residues. These 10 mutations are mutations which modify the amino acid coded for, and thus which modify the protein sequence. Deletions can be internal or terminal deletions. They can affect up to 40% of the entire sequence. Fusions consist of introducing supplemental regions at the 5' and/or 3' end of the sequence, or possibly of inserting such regions into the sequence. These modifications can be carried out with the aim 15 either of reducing or of removing the toxicity of these proteins, or of improving their production or stability, for example. Such genetic modifications can be carried out under conventional molecular biological conditions, and are illustrated in the prior art and in the remainder of the text of the present application.

More particularly, the cassettes of the invention are suitable for the 20 production of the following toxins or variants:

- The beta 2 toxin of *Clostridium perfringens* or any immunogenic fragment. The hydrophilicity profile of beta 2 toxin is shown in Figure 8. This profile shows a number of hydrophilic regions, which define particular fragments within the context of the invention. These regions are in particular located at amino acid 25 residues 40-55, 105-120, 160-170, 175-188, 200-210 and 250-260 as shown in SEQ ID n° 1. Further, fragments of the beta 2 toxin which are free of toxicity are trypsic fragments of 24, 15 and 13 kDa described in the examples. Constructions for expressing this toxin are described in the examples.
- The beta 1 toxin of *Clostridium perfringens* or any immunogenic fragment. The 30 sequence for this toxin has been described in the literature (Hunter et al., Infect.

Immun. 61 (1993), 3958-3965). Constructions for expressing this toxin are described in the examples.

- The iota toxins of *Clostridium perfringens* or any immunogenic fragment. The sequence for genes coding for iota 1 toxins (gene 1a) and iota 2 toxins (gene 1b) have been described in the literature (Perelle et al., Infect. Immun. 61 (1993) 5147-5156).
- The alpha toxin of *C. novyi* or any immunogenic fragment. The gene sequence for this toxin (tcn α gene) has been described in the literature (Hofmann et al., Mol. Gen. Genet. 247 (1995) 670-679).
- The alpha toxin of *C. septicum* or any immunogenic fragment. The gene sequence for this toxin has been described in the literature (Ballard et al., Infect. Immun. 63 (1995) 340-344).
- The A and B toxins of *C. difficile* or any immunogenic fragment. The gene sequence for this toxin has been described in the literature, as well as different immunogenic regions (Von Eichel-Streiber et al., Mol. Gen. Genet. 233 (1992) 260-268; Von Eichel-Streiber et al., J. Gen. Microbiol. 135 (1989) 55-64; Von Eichel-Streiber et al., J. Bacteriol. 174 (1992) 6707-6710).
- The epsilon toxin of *C. perfringens* (Worthington et al., Onderstepoort J. Vet. Res. 40 (4) (1973) 145-152/ Hunter et al., Infect. Immun. 60, (1992) 102-110).
- The enterotoxin of *C. perfringens* (McClane, Toxicon. 34 (1996) 1335-1343).
- The toxin of *C. chauvoei* (Crichton et al., Australian Vet. J. 63 (1986) 68).
- The L cytotoxin of *C. sordellii* or any immunogenic fragment. The gene sequence for this toxin has been described in the literature (Green et al., Gene 161 (1995) 57-61), also different immunogenic regions. In particular, this toxin is constituted by a protein of about 270 kDa and different antigenic fragments have been described.
- The pertussis toxin.
- The tetanus toxin, the botulism toxin, in particular the C fragment of these toxins which is the immunogenic fragment (Makoff et al., Bio/Technology 7 (1989) 1043; Figueiredo et al., Infect. Immun. 63 (1995) 3218-3221; Wells et al., Molecular Microbiol. 8 (1993) 1155-1162; Boucher et al., Infect. Immun. 62

(1994) 449-456; Clare et al., Bio/Technology 9 (1991) 455; Clayton et al., Infect. Immunol. 63 (1995) 2738-2742).

The nucleic acids and/or expression cassettes of the invention can be inserted in a vector which constitutes a further aspect of the present invention. It is 5 advantageously a vector which is functional in bacteria, i.e., capable of penetrating into bacteria and transporting the nucleic acids of the invention thereto. More preferably, such a vector comprises either a functional origin of replication in a bacterium, or sequences enabling it to integrate into the genome of a bacterium. More particularly, it is a plasmid, phage, episome, etc.. Further, certain vectors may 10 advantageously comprise two origins of replication, one functional in bacteria of the genus *E. coli*, and the other functional in bacteria of the *Clostridium* type, for example.

The vector of the invention is particularly preferably a vector which is functional in bacteria from the genus *Clostridium*, in particular in *Clostridium* 15 *perfringens* bacteria. As an example, it may be a vector derived from the plasmid pAT19 described by Trieu-Cuot et al. (Gene 102 (1991) 99-104). Such a derivative is, for example, the vector pMRP353 or the vector pMRP268 as shown in Figures 2-4.

The invention further concerns any recombinant cell comprising a nucleic 20 acid or an expression cassette or a vector as defined above. The recombinant cell is advantageously a prokaryote cell, preferably a bacterium. Particularly advantageously, the cell of the invention is a bacterium of the genus *Clostridium* selected from *C. absonum*, *C. baratii*, *C. bif fermentans*, *C. chauvei*, *C. difficile*, *C. 25 ghonii*, *C. lituseburens*, *C. novyi*, *C. perfringens*, *C. septicum*, *C. sordellii*, *C. subterminale* and *C. tetani*. More preferably still, it is a *C. perfringens* bacterium.

The recombinant cells of the invention can be prepared using any of the techniques known to the skilled person for introducing a nucleic acid into a cell. It may be a physical technique (electroporation, bombardment, gene gun, etc.), a 30 chemical technique (precipitation with CaPO₃, use of chemical transfer agents: cationic lipids, polymers, etc., or other methods such as cell fusion, conjugation, etc.

(Scott et al., Gene 82 (1989) 327-333; Phillips-Jones, FEMS Microbiol. Letters 66 (1990) 221-226; Allen et al., FEMS Microbiol. Letters 70 (1990) 217-220).

Further, a recombinant cell of the invention may comprise a plurality of cassettes or vectors of the invention comprising different transgenes, and thus 5 produce either different toxins, or different fragments of the same toxin.

The invention also relates to a process for producing a polypeptide comprising introducing a transgene coding for said polypeptide into a host cell under the control of a promoter as defined in the invention, then recovering said polypeptide.

10 A particular process for producing polypeptides of the invention comprises culturing a recombinant cell as defined above comprising an expression cassette or a vector, the transgene coding for said polypeptide.

More particularly, in the process of the invention, the cell is a bacterium of the genus *Clostridium*, more preferably *C. perfringens*.

15 The process of the invention is particularly suitable for the production of a toxin or a toxoid. The term "toxoid" is well known to the skilled person, and designates any inactivated form of a toxin, i.e., deprived of toxic nature, but retaining the immunological properties of the toxin. More preferably, the process of the invention is used to produce a toxin (or a corresponding toxoid) selected from 20 the group comprising the alpha, beta (beta 1 and beta 2), iota (1 and 2), epsilon and enterotoxin of *C. perfringens*, pertussis toxin, tetanus toxin, the alpha toxin of *C. septicum*, the alpha toxin of *C. noyvi*, the A and B toxins of *C. difficile* or the L cytotoxin of *C. sordellii*.

25 More generally, then, the invention concerns the use of a nucleic acid as defined above for the production of polypeptides.

The invention also concerns a process for preparing an immunogenic composition comprising the following steps:

- 30 a) expressing one or more toxins (or the corresponding toxoids) in a cell, as defined above;
- b) harvesting the supernatant;

- c) optionally, treating the supernatant to purify or concentrate the toxin(s) or toxoid(s);
- d) inactivating the toxin(s); and
- e) optionally, packaging the inactivated toxin(s) or the toxoid(s).

5 In the process of the invention, an optional supplementary step carried out before or after step d) comprises grouping the supernatant with other culture supernatant(s) containing a different or identical toxin, or a corresponding toxoid. These other supernatant or supernatants may originate from recombinant strains as defined in the invention, or from any other strain, which may or may not be 10 recombinant, producing the toxin under consideration. In the process of the invention, two supernatants are advantageously combined, which originate from cultures of recombinant bacteria of the invention producing a different toxin.

10 a) Production of supernatants

15 The first step in producing the immunogenic compositions of the invention consists of producing culture supernatants containing the toxin or toxins under consideration. At least a portion of the supernatants advantageously originate from a recombinant bacterial strain comprising a cassette or a vector as defined above. For polyvalent vaccines, a plurality or all of the supernatants can be supernatants from recombinant bacterial strains comprising a cassette or a vector as defined 20 above. More preferably, they are recombinant strains of *Clostridium*, more preferably *C. perfringens*. One advantage of the process of the invention is that it limits the number of different organisms used for fermentation. Further, the recombinant strains used can also comprise a plurality of cassettes or vectors of the invention, such that they simultaneously produce a plurality of toxins. This 25 embodiment advantageously further reduces the number of fermentations in the production process.

The production can be carried out under the culture conditions described above, in fermenters of 50 to 1500 litres. When the supernatants containing the toxins have been produced, they undergo different treatments.

30 b) Harvesting supernatants.

The supernatants are harvested using conventional biological techniques which are well known to the skilled person. In particular, the supernatants can be recovered by simple filtration to separate the cells.

c) Treatment of supernatants.

5 In order to improve the quality of the final preparation, the supernatants can optionally undergo supplementary treatments such as filtration, centrifugation, concentration, etc. These treatments clarify the supernatants, and partially purify the toxins. These techniques are known to the skilled person.

10 Further, in the case of polyvalent vaccines, different supernatants can be collected at this stage.

d) Inactivation of toxins.

15 In order to prepare an effective immunogen, it is of course important that the antigen used is free of the toxicity of the toxin against which protection is sought. With the aim of generating these inactivated toxins (toxoids), different techniques are possible (Rappuoli et al., Int. Arch. Allergy Immunol. 108 (1995) 327-333).

- Chemical inactivation

Chemical toxin inactivation has long been described, and continues to be used for numerous immunogenic preparations. Thus with the aim of inactivating bacterial toxins without affecting their immunogenic properties to too great an extent, the supernatants of the process of the invention can be treated with the following compounds: formol, β -propiolactone, iodine, formaldehyde or glutaraldehyde. More precise conditions and doses which can be used are known to the skilled person, and have been described, for example, by Rappuoli R (In Woodrow GC, Levine MM (eds): New Generation Vaccines, New York, Dekker, 1990 p. 251-268), hereby incorporated by reference.

- Physical inactivation

The toxins can also be physically inactivated, for example by irradiation.

- High pressure inactivation

30 High pressure treatment can also be used to effect inactivation.

- Genetic inactivation

A further approach to inactivating toxins resides in genetic modification of their primary structure. In this case, the products liberated into the supernatant are already toxoids, and it is not necessary to carry out a supplementary inactivation step. Genetic inactivation (or detoxification) 5 essentially consists of modifying the nucleic acids coding for the toxins, such that one or more amino acids are changed and the protein produced is free of toxicity. As an example, it is possible to replace the amino acids involved in enzymatic activity, and thus toxicity, with different amino acids which do not have this activity. It is also possible to delete regions of the 10 toxin so as to produce non-toxic, immunogenic fragments. This strategy can be carried out when epitopes of the toxins have been identified (for example by epitope scanning) or are identifiable (for example from a hydrophobicity profile). This strategy can also be applied to the production of fragments 15 (for example trypsic fragments) for which the absence of toxicity has been demonstrated. Further, genetic modification can also be carried out by random mutagenesis and selecting clones producing a toxoid. Such a strategy has already been successfully carried out to produce toxoids of the diphtheria toxin by mutagenesis using nitrosoguanidine (NTG) (Giannini et al., Nucleic Acids Res. 12 (1984) 4063-4069). Further, the production of 20 toxoids by site-specific mutagenesis has also been successfully carried out using genes of pertussis and cholera toxins (Pizza et al., Science 246 (1989) 497-500; Pizza et al., J. Exp. Med. 6 (1994) 2147-2153; Fontana et al., Infect. Immun. 63 (1995) 2356-2360).

The toxoids produced are then directly used to prepare vaccine 25 compositions.

e) Formulation

The toxoids are generally packaged using conventional pharmacological techniques in a manner suitable for vaccine use. The toxoids are preferably 30 formulated in the presence of adjuvants or excipients which are suitable for the production of injectable solutions. In particular, injection is advantageously carried out subcutaneously or systemically. The doses of antigen (toxoid) used are

generally those which will ensure the best protection without inducing a significant secondary reaction. The conditions and sites for injection, and techniques for determining doses, are illustrated in detail in the pharmacopedia (Vaccinum Clostridii Perfringentis, Chap. 363).

5 The invention also relates to any immunogenic preparation comprising a toxin produced in a recombinant strain as defined above. More particularly, the invention relates to any immunogenic preparation comprising a toxoid of recombinant beta 2 toxin, optionally combined with other toxoids.

10 The present invention will now be described in more detail with the aid of the following examples which should be considered to be illustrative in nature and are in no way limiting.

Description of the Figures

Figure 1: Cloning strategy for the complete gene for the beta 2 toxin of *C. perfringens*. H: HindIII; S: Sau3A

15 Figure 2: Schematic representation of vector pMRP268.

Figure 3: Schematic representation of vector pMRP353.

Figure 4: Schematic representation of a plasmid carrying the beta 2 promoter.

Figure 5: SDS-PAGE and Western Blot analysis of purified recombinant beta 2 toxin: (A) SDS gel (0.1%)-PAGE (10%), stained with Coomassie blue for the beta 2 recombinant toxin (4.5 μ g); (B) Corresponding Western Blot 20 obtained with anti-beta 2 antibodies.

Figure 6: Toxicity study of purified beta 2 toxin on I407 cells. Photos of I407 cells taken using a phase contrast microscope, control (A); treated with 20 μ g/ml of beta 2 toxin for 18 hours (C). (B) and (D): view of actin cytoskeleton.

25 Figure 7: Sensitivity of beta 2 toxin to trypsin. The beta 2 toxin (165 μ g/ml) was incubated without (track 7) or with 16 ng/ml (track 1), 160 ng/ml (track 2), 400 ng/ml (track 3), 1.6 μ g/ml (track 4), 4 μ g/ml (track 5) and 16 μ g/ml (track 6) of trypsin.

Figure 8: Hydrophobicity profile for beta 2 toxin.

30

List of sequences

SEQ ID n° 1: Gene sequence for beta 2 toxin of type C *Clostridium perfringens*.

SEQ ID n° 2: Sequence for beta 2 toxin gene promoter of type C *Clostridium perfringens*.

SEQ ID n° 3: Sequence for secretion signal of beta 2 toxin gene of type C
5 *Clostridium perfringens*.

SEQ ID n° 4: Sequence of primer P318.

SEQ ID n° 5: Sequence of primer P292.

Materials and methods

1. Bacterial strains and DNAs used.

10 The bacterial strains used are mentioned in Tables 1 and 2. *Clostridium* strains were cultivated in the presence of Trypticase (30 g/litre), yeast extract (20 g/litre), glucose (5 g/litre) and cysteine-HCl (0.5 g/litre), pH 7.2 (TGY medium) at 37°C under anaerobic conditions.

15 Total DNA and plasmidic DNA from *Clostridium* were extracted and purified using the technique described by Perelle et al. (Infect. Immun. 61 (1993) 5147-5156).

20 Plasmids pUC19 and pUC18 (Appligene Strasbourg, France) were used for the cloning experiments in TG1 *E. coli*, and shuttle vectors pAT19 (Trieu-Cuot et al., Gene 102 (1991) 99-104) and pJIR750 (Bannan and Rood, Plasmid 229 (1993) 233-235) were used for cloning and expression experiments in *Clostridium*, in particular in *Clostridium perfringens* 667-76, a negative lecithin strain.

- 25 2. The synthetic oligonucleotides and hybridisation experiments were those described by Perelle et al., 1993 (supra).
3. The PCR amplification experiments were carried out in a total volume of 100 µl using 100 ng of DNA as described above (Perelle et al, 1993, supra).
4. Ligations and transformations were carried out using standard molecular biological protocols (Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold spring Harbor Laboratory Press, Cold Spring Harbor, N. Y., 1989).
5. The beta 2 toxin was purified and microsequenced using the protocol described in International patent application WO 95/17521.

6. The cytotoxicity was determined using the following test: intestinal I407 cells
(ATCC) were cultivated in modified Dulbecco medium (DMEM) supplemented
with 5% of foetal calf serum. The I407 cells were spread onto 96 well culture
plates (Falcon, Becton Dickinson) and cultivated for 24 hours at 37°C in an
5 incubator containing 5% CO₂ to obtain monolayers. Series dilutions by a factor
of 2 of samples with a final volume of 100 µl were added to the monolayers. The
cells were examined after 18 hours incubation to detect any change in
morphology. The actin cytoskeleton was observed by immunofluorescence using
10 fluorescent phalloidine isothiocyanate (1 µg/ml, Sigma) using the technique
described by Giry et al. (Infect. Immun. 63 (1995) 4063-4071).

Examples

A - Cloning of the complete beta 2 toxin of type C *Clostridium perfringens*.

This example describes the cloning of the complete gene of the beta 2 toxin,
i.e., including the regulation and addressing signals at the 5' end.

15 A 676 bp fragment essentially comprising the region coding for the mature
form of the protein was isolated by amplification using the P279 and P280 deduced
by microsequencing the protein (WO 95/17521). This fragment did not include the
complete gene, in that no regulation signal was present at the 5' end of the gene.
Further, the existence of addressing sequences was not revealed nor was it deducible
20 from this fragment. With the aim of cloning the complete gene, the inventors firstly
used this fragment as a probe to isolate, by hybridisation from a gene library, a
fragment with a larger size comprising the 5' region. However, none of these
experiments either detected or obtained a corresponding fragment, whatever the
hybridisation conditions used. The inventors thus designed a different strategy to
25 attempt to isolate a fragment carrying the 5' regions of the gene. In this regard, the
inventors firstly circularised the matrix for amplification, then used inverse PCR on
the DNA thus obtained using the P292 and P318 primers the sequence of which is as
follows:

P318: 5'-GAAATGTTACAACGTATTATATCGTAG-3' (SEQ ID n° 4)

30 P292: 5'-TCAAGTTGTACATGGGATGATG-3' (SEQ ID n° 5)

The location of these primers on the gene is indicated in sequence SEQ ID n° 1. The cloning strategy is shown in Figure 1. The amplified fragment thus obtained was then sub-cloned in the pUC18 plasmid cleaved with SmaI, to generate the pMRP224 vector (Figure 1).

5 The complete 1392 bp sequence of the fragment obtained is shown in sequence SEQ ID n° 1.

B - Identification of promoter regions

The sequence obtained in Example A (SEQ ID n° 1) comprises an open reading frame coding for the mature beta 2 toxin (residues 358 to 1122), and 10 regulating or addressing regions located at the 5' and 3' end. The promoter region in the gene of the beta 2 toxin of type C *Clostridium perfringens* can be pinpointed on this sequence as comprising residues 1 to 267. This promoter sequence in the beta 2 toxin gene of type C *Clostridium perfringens* is shown separately in sequence SEQ ID n° 2. This sequence includes a consensus ribosome binding site 15 (GGGGGG) located 7 nucleotides upstream of the start codon ATG, i.e., at positions 255-260 in sequence SEQ ID n° 2.

This region, or any fragment or variation thereof, can be isolated from samples of *Clostridium* nucleic acids using suitable probes (for example corresponding to sequence SEQ ID n° 2 or a fragment thereof) or by chemical 20 synthesis, or by enzymatic digestion from the plasmids of the invention, in particular the plasmid pMRP268, deposited on 8th August 1997 at the Collection of the Institut Pasteur (CNCM: Collection Nationale de Cultures de Microorganismes), accession number I-1911.

The activity of the transcriptional promoter in this region or fragments or 25 variants can be determined in different manners, in particular by inserting this region upstream of a reporter gene, and verifying the presence of the transcription or translation product of the reporter gene in a suitable cell host, in particular a bacterium from the genus *Clostridium*, more preferably *C. perfringens*.

The reporter gene can, for example, be the LacZ gene or the gene coding for 30 luciferase.

The construction of these expression cassettes or vectors is shown in Examples D onwards, along with the transformation conditions for different cell hosts.

C - Identification of addressing regions

5 In addition to an open reading frame and transcription regulation regions (Example B), the sequence obtained in Example A (SEQ ID n° 1) also comprises addressing signals enabling a protein or peptide to be directed during synthesis towards the host cell secretion routes. The addressing region (secretion signal peptide) of the beta 2 toxin gene of type C *Clostridium perfringens* can be seen in
10 sequence SEQ ID n° 1 as including residues 268 to 357. This signal peptide sequence of the beta 2 toxin gene of type C *Clostridium perfringens* is shown separately in sequence SEQ ID n° 3. This region codes for 30 amino acids, comprising a hydrophobic region (residues 6-26), probably forming a transmembrane domain, bordered by charged amino acids (Lys2, Lys3, Lys7 and
15 Lys27). Further, the junction region between this signal sequence and the mature protein (Ala30-Lys31) corresponds to the (Ala-X) cleavage site of the major portion of bacterial signal peptidases.

This region, or any fragment or variant thereof, can be isolated from samples of *Clostridium* nucleic acids using suitable probes (for example corresponding to
20 sequence SEQ ID n° 3 or a fragment thereof) or by chemical synthesis, or by enzymatic digestion from plasmids of the invention, in particular plasmid pMRP268, deposited on 8th August 1997 in the Institut Pasteur collection (CNCM), accession number I-1911.

The signal sequence activity in this region or of fragments or variants can be
25 checked in different manners, in particular by inserting this region upstream of a reporter gene, and verifying the presence of the translation product of this reporter gene in the culture supernatant of a suitable host cell, in particular a bacterium from the genus *Clostridium*, more preferably *C. perfringens*.

The construction of expression cassettes or vectors comprising this type of
30 secretion signal is illustrated in the following examples which also give the transformation conditions in different cell hosts.

D - Construction of expression cassettes and vectors

The regulation and addressing regions described in the invention can be inserted into any conventional expression vector, or used to construct expression cassettes.

5 These cassettes and vectors are particularly suitable for expression (and optionally secretion) of recombinant proteins in bacteria from the genus *Clostridium*, in particular *Clostridium perfringens*. It should be understood that any cell type in which these regions are functional can be used. These regions are particularly advantageous for expression of bacterial toxins, in particular toxins of
10 bacteria from the genus *Clostridium*. The construction of suitable cassettes and vectors is described below.

D1. Construction of vector pMRP268 (Figure 2)

The vector pMRP268 carries the following elements:

- an origin of replication OriR enabling its replication in an *E. coli* bacterium;
- an origin of replication OriT enabling its replication in a bacterium from the genus *Clostridium*;
- two marker genes (orfE and erm) enabling transformants in *E. coli* and *Clostridium* to be selected;
- an expression cassette comprising, in the 5' → 3' direction, the promoter for the
20 beta 2 toxin of *Clostridium perfringens*, the secretion signal for the beta 2 toxin of *Clostridium perfringens*, and the sequence coding for the beta 2 toxin of *Clostridium perfringens*.

This vector was constructed from plasmid pAT19, by introducing the expression cassette into the cloning multi-site. More particularly, the cassette was obtained by amplification in the beta 2 gene of *Clostridium perfringens* of sequence SEQ ID n° 1 using primers P385 and P393, the sequence and position of which are shown in SEQ ID n° 1, using Vent Polymerase (Biolabs) following the recommendations of the manufacturer. The resulting amplification product was inserted into the EcoRI-PstI sites of plasmid pAT19. *C. perfringens* 667-76 strain 30 not expressing lecithin and containing plasmid pMRP268 was deposited at the CNCM, Institut Pasteur, on 8th August 1997, accession number I-1911.

D2. Construction of vector pMRP353 (Figure 3).

The vector pMRP353 carries the following elements:

- an origin of replication OriR enabling its replication in an *E. coli* bacterium;
- an origin of replication OriT enabling its replication in a bacterium from the genus *Clostridium*;
- two marker genes (orfE and erm) enabling transformants in *E. coli* and *Clostridium* to be selected;
- an expression cassette comprising, in the 5' → 3' direction, the promoter for the beta 2 toxin of *Clostridium perfringens*, the secretion signal for the beta 2 toxin of *Clostridium perfringens*, and the sequence coding for the beta 1 toxin of *Clostridium perfringens*.

This vector was constructed from plasmid pMRP268 by substituting the sequence coding for the beta 2 toxin of *Clostridium perfringens* by that coding for the beta 1 toxin. The cDNA coding for the beta 1 toxin was obtained by amplification from strain NTCT8533 (Table 1) using primers introducing an NcoI site at the 5' end (P321) and a PstI site at the 3' end (P322).

D3. Construction of a vector for expression of any cDNA

It is clear that the vectors described in D1 and D2 above can be used to express any cDNA of interest under the control of a promoter region from the beta 2 gene, by substitution of the coding sequence, as illustrated in Example D2. Further, equivalent vectors can be constructed from other conventional plasmidic skeletons carrying other origins of replication and selection markers.

Figure 4 represents a vector carrying the promoter for the beta 2 gene of *Clostridium perfringens*, followed by a cloning multi-site enabling any cDNA of interest to be introduced.

E - Production and purification of recombinant beta 2 protein in *Clostridium*

Plasmid pMRP268 was introduced into the *C. perfringens* 667-76 strain by electroporation (Perelle et al., 1993). The recombinant strain was cultivated overnight in a TGY medium containing 30 µg/ml of erythromycin, under anaerobic conditions at 37°C. The culture supernatant was then precipitated by saturation in the presence of 60% ammonium sulphate. The precipitate was dialysed against 10

mM Tris-HCl, pH 7.5, and charged onto a column of DEAE Sepharose CL6B. The column was then washed and eluted in the presence of 0.1 M NaCl in the same buffer. The eluted material was dialysed against 10 mM PIPES-HCl, pH 6.5, and charged onto a new column of DEAE Sepharose CL6B equilibrated with the same buffer. After washing, the column was eluted with a 0-0.1 M gradient of NaCl in a PIPES buffer. The fractions containing purified recombinant beta 2 toxin were concentrated. The apparent molecular weight of the recombinant protein, determined by SDS-PAGE, was 28 kDa, which agreed with the molecular weight calculated from the sequence (Figure 5).

10 The results obtained thus show:

- that it is possible to produce and secrete a recombinant toxin in *Clostridium* under the control of the beta 2 promoter;
- that the recombinant toxin can be purified;
- that the structure of the recombinant toxin does not appear to alter;
- 15 • that the levels of expression obtained are higher by a factor of 10 than those observed in a wild strain of *Clostridium*.

One experiment was carried out under similar conditions, but introducing the expression vector not into the 667-76 strain (which does not produce the beta 2 toxin) but into a wild *Clostridium* strain. The results obtained show that the 20 presence of the vectors of the invention in the *Clostridium* strains could increase the levels of production of the beta 2 toxin by a factor of 40 to 80.

These results demonstrate the advantages of the present invention. Thus the possibility of producing high levels of different types of toxins in a *Clostridium* strain can improve the immunogenic power of these supernatants, broaden the range 25 of vaccines to encompass toxins which are naturally produced in only small amounts, and simplify the industrial production of vaccine compositions.

F - Production of the recombinant beta 1 protein in *Clostridium*

Plasmid pMRP353 was introduced into the *C. perfringens* 667-76 strain by electroporation (Perelle et al., 1993). The recombinant strain was cultivated 30 overnight in a TGY medium containing 30 µg/ml of erythromycin under anaerobic conditions at 37°C. The culture supernatant was treated as in Example E.

This experiment demonstrated the presence of recombinant beta 1 in the supernatants.

This example thus illustrates the capacity of the constructions of the invention to produce and secrete heterologous toxins (i.e., different from beta 2 or 5 originating from pathogenic organisms other than *C. perfringens*) in *Clostridium* strains.

G - Production of immunogenic compositions

As indicated above, the present invention now enables before large 10 quantities of different types of toxins to be produced in a strain of *Clostridium* which can form part of vaccine compositions. The invention thus improves the immunogenic power of these vaccines, broadens the range of vaccines to encompass 15 toxins which are only naturally produced in small amounts, and simplifies the industrial production of vaccine compositions.

In particular, the present invention enables vaccines containing a toxoid of 15 the beta 2 toxin to be produced, i.e., an inactivated form, to induce improved protection against infections by *Clostridium*. The advantages of such compositions are illustrated by the demonstration of important toxic properties of the beta 2 toxin.

G1. Properties of the purified recombinant beta 2 toxin

Purified beta 2 toxin was intravenously injected into mice. The results 20 obtained showed that this toxin was lethal for mice in doses of less than 3 µg. Further, the results shown in Figure 6 show that the beta 2 toxin was also toxic for I407 cells.

Further, the effect of treating beta 2 with trypsin on the activity of this toxin 25 was evaluated. As shown in Figure 7, 16 ng/ml of trypsin cleaved the beta 2 toxin into a 24 kDa constituent and at higher concentrations into two 13 and 15 kDa peptides. Cytotoxicity tests carried out with these trypsic digestion products showed a total absence of toxicity. Thus trypsin induces a loss of toxicity of the beta 2 toxin, and the peptides generated can be used as toxoids.

In order to determine the importance of the beta 2 toxin in the pathogenicity 30 of *Clostridium*, the presence of the corresponding gene was analysed in 57 different strains of *Clostridium* (Tables 1 and 2). The results obtained shows that certain

strains of type B and C *Clostridium* carry the beta 2 gene. In addition, of 27 strains isolated from young swine presenting with necrotic enteritis type lesions, 44% carried the beta 2 gene. Further, only the beta 2 gene was detected in all strains isolated from horses dying from colitis symptoms and in which *Clostridium perfringens* was harvested in large quantities (over 10^6 /g) from intestinal extracts. These results show the correlation between the beta 2 toxin and certain animal diseases, and the importance of being able to generate vaccine compositions wherein one of the antigens is a toxoid of the beta 2 toxin, in particular to vaccinate young swine and horses.

10 **G2. Production of immunogenic compositions**

This example illustrates the production of immunogenic compositions or vaccine compositions for protecting the organisms concerned against infections by pathogenic bacterial strains.

15 a) Polyvalent or monovalent compositions.

As indicated above, vaccine compositions can be monovalent (directed against a single toxin) or polyvalent (directed against a plurality of toxins). Commercially available toxins are generally polyvalent (Miloxan, Glevax5). Preferred immunogenic compositions of the invention are also polyvalent. The immunogenic compositions of the invention advantageously comprise at least one recombinant toxoid produced in a recombinant cell of the invention. A further preferred immunogenic composition in the context of the invention advantageously comprises a toxoid of the beta 2 toxin of *C. perfringens*. The immunogenic compositions of the invention can also comprise any toxin mentioned above.

20 b) Production of an immunogenic composition against the beta 2 toxin

In order to prepare such a composition, the culture supernatant from the *C. perfringens* strain transformed by the vector pMRP268 (Example E) was harvested using conventional techniques. This supernatant was centrifuged, then filtered and concentrated to obtain a preparation which was enriched in recombinant beta toxins. This preparation was then treated with formol to inactivate the toxins present. The 25 treatment efficiency was determined by incubating I407 cells in the presence of a sample of this preparation.

This preparation was then used as an immunogen to induce the production of antibodies in an organism. The capacity of the antibodies produced to inhibit an infection by pathogenic strains of *Clostridium* could then be determined as described in the pharmacopia (Vaccinum *Clostridium perfringens*).

5 c) Production of a polyvalent immunogenic composition

In order to prepare such a composition, the enriched composition obtained in Example b) above was mixed, before or after inactivation, with one or more other culture supernatants or derivative preparations comprising a toxin or the corresponding toxoid, such as a pertussis, cholera and/or tetanus toxoid. The 10 resulting preparation was then checked and used as described in Example b).

PRINTED IN U.S.A. ON RECYCLED PAPER

TABLE 1

Strains of type C <i>C. perfringens</i>	Presence of beta 2 toxin gene
NCTC8533	-
NCTC6121	-
ATCC3628	-
NCTC8081	-
NCTC3180	+
NCTC3182	+

TABLE 2

Isolates from	Total <i>Clostridium</i>	Presence of genes		
		cpb2+, cpb1-	cpb2+, cpb1+	cpb2-, cpb1-
Young swine	27	12	12	1
Horses	15	16	0	0
Foodstuffs	15	2	0	0

cpb2: gene of beta 2 toxin; cpb1: gene of beta 1 toxin

CLAIMS

1. A nucleic acid characterized in that it has a transcriptional promoter activity and in that it comprises:
 - (a) all or a portion of sequence SEQ ID n° 2 or a variant thereof; or
 - (b) a sequence hybridising with all or part of the complementary strand of sequence SEQ ID n° 2.
2. A nucleic acid according to claim 1, characterized in that it comprises all or a portion of sequence SEQ ID n° 2.
3. A nucleic acid according to claim 1 or claim 2, characterized in that it is a promoter of the gene for the beta 2 toxin of *Clostridium perfringens* or a fragment thereof.
4. A cassette for expression of a transgene, characterized in that it comprises, in the 5' → 3' direction:
 - a nucleic acid according to claim 1; and
 - said transgene.
5. An expression cassette according to claim 4, characterized in that it further comprises a transcriptional terminator at the 3' end of the transgene.
6. An expression cassette according to claim 4 or claim 5, characterized in that it further comprises a secretion signal between the nucleic acid and the transgene.
7. An expression cassette according to any one of claims 4 to 6, characterized in that the transgene codes for a toxin or a fragment or a variant of the toxin.
8. An expression cassette according to claim 7, characterized in that the transgene codes for a toxin or a fragment or variant of a toxin of a pathogenic bacterium.
9. A vector comprising a nucleic acid according to claim 1 or an expression cassette according to claim 4.
10. A vector according to claim 9, characterized in that it is functional in bacteria.

11. A vector according to claim 10, characterized in that it is functional in bacteria of the genus *Clostridium*, in particular in *Clostridium perfringens* bacteria.
12. A recombinant cell comprising a nucleic acid according to claim 1 or an expression cassette according to claim 4 or a vector according to claim 9.
13. A cell according to claim 12, characterized in that it is a prokaryote cell, preferably a bacterium.
14. A process for producing a polypeptide, comprising introducing into a host cell a transgene coding for said polypeptide under the control of a promoter as defined in claim 1, then recovering said polypeptide.
15. A process for producing a polypeptide, characterized in that it comprises culturing a recombinant cell according to claim 12 comprising an expression cassette according to claim 4 or a vector according to claim 9, the transgene coding for said polypeptide.
16. A process according to claim 14 or claim 15, characterized in that the cell is a bacterium from the genus *Clostridium*.
17. A process according to any one of claims 14 to 16 for producing a toxin or a toxoid.
18. Use of a nucleic acid according to claim 1 for producing polypeptides.
19. A nucleic acid comprising all or a portion of sequence SEQ ID n° 3.
20. A process for preparing an immunogenic composition comprising the following steps:
 - a) expressing one or more toxins (or the corresponding toxoids) in a cell according to claim 12;
 - b) harvesting the supernatant;
 - c) optionally, treating the supernatant to purify or concentrate the toxin(s) or toxoid(s);
 - d) inactivating the toxin(s); and
 - e) optionally, packaging the inactivated toxin(s) or toxoid(s).
21. An immunogenic composition comprising a toxoid of a toxin produced according to the process of claim 17.

22. An immunogenic composition comprising a toxoid of a recombinant beta 2 toxin.
23. Essentially purified recombinant beta 2 toxin.




FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5




FIGURE 6



FIGURE 7






FIGURE 8A




FIGURE 8B

Séquence SEQ ID n° 1

1 ATTTGGGATATCTTAAATTAGCACAGAAGAATGTTAAATGAAATAAAGATAATAAAA
 -----> P385

61 GATATATTAATTATAGCTGAAAATTATAATTATATGATAAGTATAGTTAATAAATAA
 121 AAAGTGTCTCGGGGGACACTTTTGTAAAAGGAAAATATAAATAAAATTAGAT
 181 AAAAGTGTAAAATAATTATTTTAAATTGTAAAATTGATATAATTGAAATTG
 241 TAAAAAAAATTTCAGGGGGAAATATAAATGAAAAAAATTATTCAGTTACTGTAATT
 1 M K K I I S K F T V I
 301 TTTATGTTTCATGTTTCTTATTGTTGGAGCAATAAGTCCAATGAAAGCAAGTGCAAAA
 12 F M F S C F L I V G A I S P M K A S A K
 361 GAAATCGACGCTTATAGAAAGGTAAATGGAGAATTATCTTAATGCTTAAAAAACTACGAT
 32 E I D A Y R K V M E N Y L N A L K N Y D
 421 ATTAATACAGTTGAAACATTTCAGAAGAGTAAATAATGTTGAAACAGTATAGA
 52 I N T V V N I S E D E R V N N V E Q Y R
 481 GAAATGTTAGAAGATTAAATATGATCCTAACCAACAACGAAATCTTTGAAATACTT
 72 E M L E D F K Y D P N Q Q L K S F E I L
 541 AATTCAACAAAAGAGCGATAATAAAGAAATATTTAATGTAACACTGAATTTTAAATGGT0
 92 N S Q K S D N K E I F N V K T E F L N G
 601 GCAATTATGATATGGAATTACTGTATCATCTAAAGATGGAAAATTAAATAGTATCTGAT
 112 A I Y D M E F T V S S K D G K L I V S D
 661 ATGGAAAGAACAAAAGTTGAGAATGAAGGAAAATATATTAAACACCATCATTTAGAACT
 132 M E R T K V E N E G K Y I L T P S F R T
 721 CAAGTTGTACATGGGATGATGAACTAGCACAAGCAATTGGGGAGTTATCCACAAACA
 152 Q V C T W D D E L A Q A I G G V Y P Q T
 781 TATTCTGATAGATTACATATTATGCAGATAATAATTATTAAACTTCAGACAATATGCA
 172 Y S D R F T Y Y A D N I L L N F R Q Y A
 841 ACTTCAGTTCAAGAGATTAAAGTAGAATATAGTGTGTAGATCATTGGATGTGGAAA
 192 T S G S R D L K V E Y S V V D H W M W K
 901 GATGATGTTAAAGCTCTCAAATGGTATATGGTCAAAATCCTGATTCTGCTAGACAAATA
 212 D D V K A S Q M V Y G Q N P D S A R Q I
 961 AGATTATATAGAAAAGGACAATCTTCTATAAAATATAGAATAAGAATTAAAAACTTT
 232 R L Y I E K G Q S F Y K Y R I R I K N F
 1021 ACACCTGCATCAATTAGAGTATTGGTGAAGGGTATTGTGCATAGAAAAAAATATGAACT
 252 T P A S I R V F G E G Y C A * <-----
 1081 GACTTAGTCACTCATATTTTTACTATTAAATTATATAAAACCTAACATACA
 ----->
 1141 TGAAAGTATTCTTAATACAGTTATCAAAATTAAAGTAGGGAAATAAAATAAAAGGCT
 1201 AAAAACTATATTAAAAACTATAAAATTATTAATTAGGTTTAAGGTGTATATTATT
 1261 TATGATTATAGGAATAATGCCAAATGGAATAATAAAAGTAATATTAAATAATTGGTC
 1321 TAAAAAGTATACATCATTGATAAAAGAAAAATTACCAAGTAAAATTGAGCTTAAAAAATT
 P393 <-----
 1381 AAATGTAATT 1392

Séquence SEQ ID n° 2

1 ATTTGGGATATCTTAAATTAGCACAGAAGAATGTTAAATGAAATAAAGATAATAAAAAA
 -----> P385
 61 GATATATTAATTATAGCTGAAAATTATAATTATGATAAGTATAAGTTAATAAATAA
 121 AAAGTGTCTCGGGGGACACTTTTGTAAAAAGGAAATATAAATAAAATTAGAT
 181 AAAAGTGTAAAATAATTATTTTATTAAATTGTAAAAATTGATATAATTGAATTG
 241 TAAAAAAAATTCAGGGGGATATAAATGAAAAAAATTATTCAAAGTTACTGTAATT
 1
 301 TTTATGTTTCATGTTTCTTATTGTT

Séquence SEQ ID n° 3

10

M K K I I S K F T V I
 GGAGCAATAAGTCCAATGAAAGCAAGTGCAAAA
 F M F S C F L I V G A I S P M K A S A
 GAAATCGACGCTTATAGAAAGGTAAATGGAGAATTATCTTAATGCTTAAAAACTAC

15

Séquence SEQ ID n° 4

P318 : 5'-GAAATGTTACAACTGTATTAATATCGTAG-3'

20

Séquence SEQ ID n° 5

P292 : 5'-TCAAGTTGTACATGGATGATG-3'

25